MorphoSys AG (MorphoSys)

Oncology Corporate Profile

HQ Location

Lena-Christ-Strasse 48
82152 Martinsried, Planegg, G

Company Description

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.

Website: http://www.morphosys.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
xentuzumab / BI-836845HuCAL antibodyBreast cancerIIBoehringer Ingelheim
xentuzumab / BI-836845HuCAL antibodyCastration-resistant Prostate cancer (CRPC)IIBoehringer Ingelheim
MOR208anti-CD19 monoclonal antibody (humanized)Chronic lymphocytic Leukemia (CLL)II
MOR208anti-CD19 monoclonal antibody (humanized)Chronic Lymphocytic Leukemia (CLL)II
MOR208anti-CD19 monoclonal antibody (humanized)Diffuse large B-cell Lymphoma (DLBCL)II
anetumab ravtansineHuCAL-based antibody drug conjugateMesotheliomaII
MOR202anti-CD38 monoclonal antibodyMultiple MyelomaII
BHQ880HuCAL antibodyMultiple MyelomaIINovartis
tarextumab / OMP-59R5HuCAL antibodyNon Small Cell Lung Cancer (NSCLC)IIOncoMed
utomilumab (+ avelumab) / PF-05082566HuCAL antibodyVarious cancer typesIIPfizer
tarextumab / OMP-59R5HuCAL antibodyVarious cancer typesIIOncoMed
vantictumab / OMP-18R5HuCAL antibodyBreast cancerIOncoMed
vantictumab / OMP-18R5HuCAL antibodyNon Small Cell Lung CancerIOncoMed
xentuzumab / BI-836845HuCAL antibodyNon Small Cell Lung Cancer (NSCLC)IBoehringer Ingelheim
utomilumab (+ rituximab)HuCAL antibodyNon-Hodgkin's Lymphoma (NHL)IPfizer
vantictumab / OMP-18R5HuCAL antibodyPancreatic cancerIOncoMed
MOR209/ES414anti-PSMA/anti-CD3 bi-specific antibodyProstate cancerI
anetumab ravtansineHuCAL-based antibody drug conjugateVarious cancer typesI
anetumab ravtansine (+ doxorubicin)HuCAL-based antibody drug conjugateVarious cancer typesI
utomilumab (+ rituximab)HuCAL antibodyVarious cancer typesIPfizer
utomilumab (+ mogamulizumab)HuCAL antibodyVarious cancer typesIPfizer
utomilumab (+ pembrolizumab)HuCAL antibodyVarious cancer typesIPfizer
utomilumab (+ PF-04518600)HuCAL antibodyVarious cancer typesIPfizer

View additional information on product candidates here »

Source: http://www.morphosys.com/

Recent News Headlines

There are no news items to display